Serum triglycerides and risk of cardiovascular disease

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1821, Issue 5, 2012, Pages 867-875

  Boullart, A C I ^a   De Graaf, J ^a   Stalenhoef, A F ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cardiovascular disease; Hypertriglyceridemia; Lipid lowering drug; Metabolism; Triglyceride

Indexed keywords

APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; ATORVASTATIN; BINDING PROTEIN; CHOLESTEROL; CHYLOMICRON; EZETIMIBE; FIBRIC ACID DERIVATIVE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; SATURATED FATTY ACID; TRIACYLGLYCEROL;

ATHEROSCLEROSIS; BLOOD VESSEL; CALORIC RESTRICTION; CARBOHYDRATE INTAKE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL STUDY; CONCENTRATION (PARAMETERS); DISEASE ASSOCIATION; DISEASE CLASSIFICATION; ENDOTHELIUM CELL; ENZYME ACTIVATION; EXERCISE; FAT INTAKE; HETEROZYGOSITY; HUMAN; HYDROPHOBICITY; HYPERTRIGLYCERIDEMIA; INTESTINE CELL; LIFESTYLE MODIFICATION; LIPID COMPOSITION; LIPID METABOLISM; LIPID TRANSPORT; MEASUREMENT; META ANALYSIS (TOPIC); PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN HYDROLYSIS; PROTEIN SECRETION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SMALL INTESTINE; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; VASODILATATION; WEIGHT REDUCTION;

CARDIOVASCULAR DISEASES; CHOLESTEROL; HUMANS; HYPERTRIGLYCERIDEMIA; LIPID METABOLISM; RISK FACTORS; TRIGLYCERIDES;

EID: 84859161050     PISSN: 13881981     EISSN: 18792618     Source Type: Journal    
DOI: 10.1016/j.bbalip.2011.10.002     Document Type: Review

References (117)

1. R.C. Turner, H. Millns, H.A. Neil, I.M. Stratton, S.E. Manley, D.R. Matthews, and R.R. Holman Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23) BMJ 316 1998 823 828 (Clinical research ed)
2. P.N. Durrington Triglycerides are more important in atherosclerosis than epidemiology has suggested Atherosclerosis 141 Suppl 1 1998 S57 S62
3. W.B. Kannel, and R.S. Vasan Triglycerides as vascular risk factors: new epidemiologic insights Curr. Opin. Cardiol. 24 2009 345 350
4. M.D. Carroll, D.A. Lacher, P.D. Sorlie, J.I. Cleeman, D.J. Gordon, M. Wolz, S.M. Grundy, and C.L. Johnson Trends in serum lipids and lipoproteins of adults, 1960-2002 JAMA 294 2005 1773 1781
5. S.G. Young, B.S. Davies, L.G. Fong, P. Gin, M.M. Weinstein, A. Bensadoun, and A.P. Beigneux GPIHBP1: an endothelial cell molecule important for the lipolytic processing of chylomicrons Curr. Opin. Lipidol. 18 2007 389 396
6. A.F. Stalenhoef, M.J. Malloy, J.P. Kane, and R.J. Havel Metabolism of apolipoproteins B-48 and B-100 of triglyceride-rich lipoproteins in normal and lipoprotein lipase-deficient humans Proc. Natl. Acad. Sci. U. S. A. 81 1984 1839 1843
7. A. Minnich, B.G. Nordestgaard, and D.B. Zilversmit A novel explanation for the reduced LDL cholesterol in severe hypertriglyceridemia J. Lipid Res. 30 1989 347 355
8. J.E. Groener, A.J. Van Rozen, and D.W. Erkelens Cholesteryl ester transfer activity. Localization and role in distribution of cholesteryl ester among lipoproteins in man Atherosclerosis 50 1984 261 271
9. D.B. Zilversmit Atherogenic nature of triglycerides, postprandial lipidemia, and triglyceride-rich remnant lipoproteins Clin. Chem. 41 1995 153 158
10. R.J. Havel Postprandial hyperlipidemia and remnant lipoproteins Curr. Opin. Lipidol. 5 1994 102 109
11. C. Marcoux, P.N. Hopkins, T. Wang, E.T. Leary, K. Nakajima, J. Davignon, and J.S. Cohn Remnant-like particle cholesterol and triglyceride levels of hypertriglyceridemic patients in the fed and fasted state J. Lipid Res. 41 2000 1428 1436
12. B.G. Nordestgaard, M. Benn, P. Schnohr, and A. Tybjaerg-Hansen Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women JAMA 298 2007 299 308
13. R. Batal, M. Tremblay, P.H. Barrett, H. Jacques, A. Fredenrich, O. Mamer, J. Davignon, and J.S. Cohn Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects J. Lipid Res. 41 2000 706 718
14. J. Bjorkegren, F. Karpe, R.W. Milne, and A. Hamsten Differences in apolipoprotein and lipid composition between human chylomicron remnants and very low density lipoproteins isolated from fasting and postprandial plasma J. Lipid Res. 39 1998 1412 1420
15. J.H. Bae, E. Bassenge, K.B. Kim, Y.N. Kim, K.S. Kim, H.J. Lee, K.C. Moon, M.S. Lee, K.Y. Park, and M. Schwemmer Postprandial hypertriglyceridemia impairs endothelial function by enhanced oxidant stress Atherosclerosis 155 2001 517 523
16. R.A. Vogel, M.C. Corretti, and G.D. Plotnick Effect of a single high-fat meal on endothelial function in healthy subjects Am. J. Cardiol. 79 1997 350 354
17. B.G. Nordestgaard, A. Tybjaerg-Hansen, and B. Lewis Influx in vivo of low density, intermediate density, and very low density lipoproteins into aortic intimas of genetically hyperlipidemic rabbits. Roles of plasma concentrations, extent of aortic lesion, and lipoprotein particle size as determinants Arterioscler. Thromb. 12 1992 6 18
18. S. Stender, and D.B. Zilversmit Transfer of plasma lipoprotein components and of plasma proteins into aortas of cholesterol-fed rabbits. Molecular size as a determinant of plasma lipoprotein influx Arteriosclerosis 1 1981 38 49 Dallas, Tex
19. S. Stender, and E. Hjelms In vivo transfer of cholesteryl ester from high and low density plasma lipoproteins into human aortic tissue Arteriosclerosis 8 1988 252 262 Dallas, Tex
20. B.G. Nordestgaard, and D.B. Zilversmit Large lipoproteins are excluded from the arterial wall in diabetic cholesterol-fed rabbits J. Lipid Res. 29 1988 1491 1500
21. C.E. Niehaus, A. Nicoll, R. Wootton, B. Williams, J. Lewis, D.J. Coltart, and B. Lewis Influence of lipid concentrations and age on transfer of plasma lipoprotein into human arterial intima Lancet 2 1977 469 471
22. B.G. Nordestgaard, R. Wootton, and B. Lewis Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media Arterioscler. Thromb. Vasc. Biol. 15 1995 534 542
23. M.A. Austin, M.C. King, K.M. Vranizan, and R.M. Krauss Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk Circulation 82 1990 495 506
24. K.K. Berneis, and R.M. Krauss Metabolic origins and clinical significance of LDL heterogeneity J. Lipid Res. 43 2002 1363 1379
25. G.K. Hansson Inflammation, atherosclerosis, and coronary artery disease N. Engl. J. Med. 352 2005 1685 1695
26. N. Leitinger Oxidized phospholipids as modulators of inflammation in atherosclerosis Curr. Opin. Lipidol. 14 2003 421 430
27. I. Tabas, K.J. Williams, and J. Boren Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications Circulation 116 2007 1832 1844
28. J. Frostegard, A.K. Ulfgren, P. Nyberg, U. Hedin, J. Swedenborg, U. Andersson, and G.K. Hansson Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines Atherosclerosis 145 1999 33 43
29. S. Kofler, T. Nickel, and M. Weis Role of cytokines in cardiovascular diseases: a focus on endothelial responses to inflammation Clin. Sci. (Lond.) 108 2005 205 213
30. G.K. Hansson Immune mechanisms in atherosclerosis Arterioscler. Thromb. Vasc. Biol. 21 2001 1876 1890
31. M.R. Taskinen Diabetic dyslipidaemia: from basic research to clinical practice Diabetologia 46 2003 733 749
32. N. Sarwar, M.S. Sandhu, S.L. Ricketts, A.S. Butterworth, E. Di Angelantonio, S.M. Boekholdt, W. Ouwehand, H. Watkins, N.J. Samani, D. Saleheen, D. Lawlor, M.P. Reilly, A.D. Hingorani, P.J. Talmud, and J. Danesh Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies Lancet 375 2010 1634 1639
33. R. Scott, R. O'Brien, G. Fulcher, C. Pardy, M. D'Emden, D. Tse, M.R. Taskinen, C. Ehnholm, and A. Keech Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study Diabetes Care 32 2009 493 498
34. Y.I. Wang, J. Schulze, N. Raymond, T. Tomita, K. Tam, S.I. Simon, and A.G. Passerini Endothelial inflammation correlates with subject triglycerides and waist size after a high-fat meal Am. J. Physiol. 300 2010 H784 H791
35. D.C. Chan, and G.F. Watts Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies Expert Opin. Pharmacother. 12 2011 13 30
36. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), Jama 285 (2001) 2486-2497.
37. H.S. Cabin, and W.C. Roberts Relation of serum total cholesterol and triglyceride levels to the amount and extent of coronary arterial narrowing by atherosclerotic plaque in coronary heart disease. Quantitative analysis of 2037 five mm segments of 160 major epicardial coronary arteries in 40 necropsy patients Am. J. Med. 73 1982 227 234
38. J.D.B. L. Berglund, A.C. Goldberg, I.J. Goldberg, F. Sacks, M.H. Murad, A.F. Stalenhoef, Evaluation and treatment of hypertriglyceridemia: an Endocrine Society Clinical Practice Guideline, Journal of Clinical Endocrinology and Metabolism (in press).
39. CDCP Prevalence of abnormal lipid levels among youths-United States, 1999-2006 Mmwr 59 2010 29 33
40. J.P. van Wijk, C.J. Halkes, P.P. De Jaegere, H.W. Plokker, D.W. Erkelens, and M.C. Cabezas Normalization of daytime triglyceridemia by simvastatin in fasting normotriglyceridemic patients with premature coronary sclerosis Atherosclerosis 171 2003 109 116
41. L.E. Eberly, J. Stamler, and J.D. Neaton Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease Arch. Intern. Med. 163 2003 1077 1083
42. A. Langsted, J.J. Freiberg, A. Tybjaerg-Hansen, P. Schnohr, G.B. Jensen, and B.G. Nordestgaard Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow-up J. Intern. Med. 270 2011 65 75
43. A. Varbo, B.G. Nordestgaard, A. Tybjaerg-Hansen, P. Schnohr, G.B. Jensen, and M. Benn Nonfasting triglycerides, cholesterol, and ischemic stroke in the general population Ann. Neurol. 69 2011 628 634
44. J.R. Nofer Hyperlipidemia and cardiovascular disease: triglycerides-a revival of cardiovascular risk factor? Curr. Opin. Lipidol. 22 2011 319 321
45. G.D. Kolovou, D.P. Mikhailidis, J. Kovar, D. Lairon, B.G. Nordestgaard, T.C. Ooi, P. Perez-Martinez, H. Bilianou, K. Anagnostopoulou, and G. Panotopoulos Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement Curr. Vasc. Pharmacol. 9 2011 258 270
46. J.D. Brunzell Familial lipoprotein lipase deficiency The Metabolic Basis of Inherited Disease 8 ed 2001 McGraw-Hill New York 2789 2816
47. R.A. Hegele Monogenic dyslipidemias: window on determinants of plasma lipoprotein metabolism Am. J. Hum. Genet. 69 2001 1161 1177
48. G. Olivecrona, E. Ehrenborg, H. Semb, E. Makoveichuk, A. Lindberg, M.R. Hayden, P. Gin, B.S. Davies, M.M. Weinstein, L.G. Fong, A.P. Beigneux, S.G. Young, T. Olivecrona, and O. Hernell Mutation of conserved cysteines in the Ly6 domain of GPIHBP1 in familial chylomicronemia J. Lipid Res. 51 2010 1535 1545
49. J.L. Goldstein, H.G. Schrott, W.R. Hazzard, E.L. Bierman, and A.G. Motulsky Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia J. Clin. Invest. 52 1973 1544 1568
50. J.J. Genest Jr., S.S. Martin-Munley, J.R. McNamara, J.M. Ordovas, J. Jenner, R.H. Myers, S.R. Silberman, P.W. Wilson, D.N. Salem, and E.J. Schaefer Familial lipoprotein disorders in patients with premature coronary artery disease Circulation 85 1992 2025 2033
51. M.J. Veerkamp, J. de Graaf, J.C. Hendriks, P.N. Demacker, and A.F. Stalenhoef Nomogram to diagnose familial combined hyperlipidemia on the basis of results of a 5-year follow-up study Circulation 109 2004 2980 2985
52. C.C. Walden, and R.A. Hegele Apolipoprotein E in hyperlipidemia Ann. Intern. Med. 120 1994 1026 1036
53. G. Yuan, K.Z. Al-Shali, and R.A. Hegele Hypertriglyceridemia: its etiology, effects and treatment Cmaj 176 2007 1113 1120
54. A.L. Catapano, Z. Reiner, G. De Backer, I. Graham, M.R. Taskinen, O. Wiklund, S. Agewall, E. Alegria, M.J. Chapman, P. Durrington, S. Erdine, J. Halcox, R. Hobbs, J. Kjekshus, P. Perrone Filardi, G. Riccardi, R.F. Storey, and D. Wood ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Atherosclerosis 217 Suppl 1 2011 1 44
55. T.A. Jacobson, M. Miller, and E.J. Schaefer Hypertriglyceridemia and cardiovascular risk reduction Clin. Ther. 29 2007 763 777
56. D. Brunner, S. Altman, K. Loebl, S. Schwartz, and S. Levin Serum cholesterol and triglycerides in patients suffering from ischemic heart disease and in healthy subjects Atherosclerosis 28 1977 197 204
57. M.F. Reardon, P.J. Nestel, I.H. Craig, and R.W. Harper Lipoprotein predictors of the severity of coronary artery disease in men and women Circulation 71 1985 881 888
58. E. Lindenstrom, G. Boysen, and J. Nyboe Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen City Heart Study BMJ 309 1994 11 15 Clinical research ed
59. J.E. Hokanson, and M.A. Austin Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies J. Cardiovasc. Risk 3 1996 213 219
60. G. Assmann, P. Cullen, and H. Schulte The Munster Heart Study (PROCAM). Results of follow-up at 8 years Eur. Heart J. 19 Suppl A 1998 A2 A11
61. A. Patel, F. Barzi, K. Jamrozik, T.H. Lam, H. Ueshima, G. Whitlock, and M. Woodward Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region Circulation 110 2004 2678 2686
62. S. Bansal, J.E. Buring, N. Rifai, S. Mora, F.M. Sacks, and P.M. Ridker Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women JAMA 298 2007 309 316
63. N. Sarwar, J. Danesh, G. Eiriksdottir, G. Sigurdsson, N. Wareham, S. Bingham, S.M. Boekholdt, K.T. Khaw, and V. Gudnason Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies Circulation 115 2007 450 458
64. L.S. Jonsdottir, N. Sigfusson, V. Gudnason, H. Sigvaldason, and G. Thorgeirsson Do lipids, blood pressure, diabetes, and smoking confer equal risk of myocardial infarction in women as in men? The Reykjavik Study J. Cardiovasc. Risk 9 2002 67 76
65. N. Day, S. Oakes, R. Luben, K.T. Khaw, S. Bingham, A. Welch, and N. Wareham EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer Br. J. Cancer 80 Suppl 1 1999 95 103
66. A. Tirosh, A. Rudich, T. Shochat, D. Tekes-Manova, E. Israeli, Y. Henkin, I. Kochba, and I. Shai Changes in triglyceride levels and risk for coronary heart disease in young men Ann. Intern. Med. 147 2007 377 385
67. A. Bonaventure, T. Kurth, F. Pico, P. Barberger-Gateau, K. Ritchie, C. Stapf, and C. Tzourio Triglycerides and risk of hemorrhagic stroke vs. ischemic vascular events: the Three-city Study Atherosclerosis 210 2010 243 248
68. J.J. Freiberg, A. Tybjaerg-Hansen, J.S. Jensen, and B.G. Nordestgaard Nonfasting triglycerides and risk of ischemic stroke in the general population JAMA 300 2008 2142 2152
69. E. Di Angelantonio, N. Sarwar, P. Perry, S. Kaptoge, K.K. Ray, A. Thompson, A.M. Wood, S. Lewington, N. Sattar, C.J. Packard, R. Collins, S.G. Thompson, and J. Danesh Major lipids, apolipoproteins, and risk of vascular disease JAMA 302 2009 1993 2000
70. H.A. Neil, J. Cooper, D.J. Betteridge, N. Capps, I.F. McDowell, P.N. Durrington, M. Seed, J.I. Mann, and S.E. Humphries All-cause and cardiovascular mortality in treated patients with severe hypertriglyceridaemia: a long-term prospective registry study Atherosclerosis 211 2010 618 623
71. B.G. Nordestgaard, S. Stender, and K. Kjeldsen Reduced atherogenesis in cholesterol-fed diabetic rabbits. Giant lipoproteins do not enter the arterial wall Arteriosclerosis 8 1988 421 428 Dallas, Tex
72. A.P. van de Woestijne, H. Monajemi, E. Kalkhoven, and F.L. Visseren Adipose tissue dysfunction and hypertriglyceridemia: mechanisms and management Obes. Rev. 12 10 2011 829 840
73. H. Yokoyama, M. Emoto, T. Araki, S. Fujiwara, K. Motoyama, T. Morioka, H. Koyama, T. Shoji, Y. Okuno, and Y. Nishizawa Effect of aerobic exercise on plasma adiponectin levels and insulin resistance in type 2 diabetes Diabetes Care 27 2004 1756 1758
74. M.T. Hamilton, D.G. Hamilton, and T.W. Zderic Role of low energy expenditure and sitting in obesity, metabolic syndrome, type 2 diabetes, and cardiovascular disease Diabetes 56 2007 2655 2667
75. V. Bamba, and D.J. Rader Obesity and atherogenic dyslipidemia Gastroenterology 132 2007 2181 2190
76. C.C. Case, P.H. Jones, K. Nelson, E. O'Brian Smith, and C.M. Ballantyne Impact of weight loss on the metabolic syndrome Diabetes Obes. Metab. 4 2002 407 414
77. W.E. Kraus, J.A. Houmard, B.D. Duscha, K.J. Knetzger, M.B. Wharton, J.S. McCartney, C.W. Bales, S. Henes, G.P. Samsa, J.D. Otvos, K.R. Kulkarni, and C.A. Slentz Effects of the amount and intensity of exercise on plasma lipoproteins N. Engl. J. Med. 347 2002 1483 1492
78. K.G. Parhofer, E. Laubach, and P.H. Barrett Effect of atorvastatin on postprandial lipoprotein metabolism in hypertriglyceridemic patients J. Lipid Res. 44 2003 1192 1198
79. P.M. Kearney, L. Blackwell, R. Collins, A. Keech, J. Simes, R. Peto, J. Armitage, and C. Baigent Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis Lancet 371 2008 117 125
80. J.C. Fruchart, F. Sacks, M.P. Hermans, G. Assmann, W.V. Brown, R. Ceska, M.J. Chapman, P.M. Dodson, P. Fioretto, H.N. Ginsberg, T. Kadowaki, J.M. Lablanche, N. Marx, J. Plutzky, Z. Reiner, R.S. Rosenson, B. Staels, J.K. Stock, R. Sy, C. Wanner, A. Zambon, and P. Zimmet The residual risk reduction initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia Am. J. Cardiol. 102 2008 1K 34K
81. S.J. Nicholls, G. Brandrup-Wognsen, M. Palmer, and P.J. Barter Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER) Am. J. Cardiol. 105 2010 69 76
82. F. Karpe, and K.N. Frayn The nicotinic acid receptor-a new mechanism for an old drug Lancet 363 2004 1892 1894
83. V.S. Kamanna, and M.L. Kashyap Mechanism of action of niacin Am. J. Cardiol. 101 2008 20B 26B
84. C.D. Meyers, V.S. Kamanna, and M.L. Kashyap Niacin therapy in atherosclerosis Curr. Opin. Lipidol. 15 2004 659 665
85. A.-H. investigators The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol rationale and study design. The atherothrombosis intervention in metabolic syndrome with low HDL/high triglycerides: impact on global health outcomes (AIM-HIGH) Am. Heart J. 161 2011 471 477 e472
86. B. Staels, J. Dallongeville, J. Auwerx, K. Schoonjans, E. Leitersdorf, and J.C. Fruchart Mechanism of action of fibrates on lipid and lipoprotein metabolism Circulation 98 1998 2088 2093
87. N. Marx, H. Duez, J.C. Fruchart, and B. Staels Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells Circ. Res. 94 2004 1168 1178
88. E.Y. Chew, W.T. Ambrosius, M.D. Davis, R.P. Danis, S. Gangaputra, C.M. Greven, L. Hubbard, B.A. Esser, J.F. Lovato, L.H. Perdue, D.C. Goff Jr., W.C. Cushman, H.N. Ginsberg, M.B. Elam, S. Genuth, H.C. Gerstein, U. Schubart, and L.J. Fine Effects of medical therapies on retinopathy progression in type 2 diabetes N. Engl. J. Med. 363 2010 233 244
89. H.N. Ginsberg, M.B. Elam, L.C. Lovato, J.R. Crouse III, L.A. Leiter, P. Linz, W.T. Friedewald, J.B. Buse, H.C. Gerstein, J. Probstfield, R.H. Grimm, F. Ismail-Beigi, J.T. Bigger, D.C. Goff Jr., W.C. Cushman, D.G. Simons-Morton, and R.P. Byington Effects of combination lipid therapy in type 2 diabetes mellitus N. Engl. J. Med. 362 2010 1563 1574
90. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study, Circulation 102 (2000) 21-27.
91. V. Manninen, L. Tenkanen, P. Koskinen, J.K. Huttunen, M. Manttari, O.P. Heinonen, and M.H. Frick Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment Circulation 85 1992 37 45
92. S.J. Robins, D. Collins, J.T. Wittes, V. Papademetriou, P.C. Deedwania, E.J. Schaefer, J.R. McNamara, M.L. Kashyap, J.M. Hershman, L.F. Wexler, and H.B. Rubins Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial JAMA 285 2001 1585 1591
93. F.M. Sacks, V.J. Carey, and J.C. Fruchart Combination lipid therapy in type 2 diabetes N. Engl. J. Med. 363 2011 692 694
94. author reply 694-695.
95. M. Jun, C. Foote, J. Lv, B. Neal, A. Patel, S.J. Nicholls, D.E. Grobbee, A. Cass, J. Chalmers, and V. Perkovic Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis Lancet 375 2010 1875 1884
96. G.F. Watts, and F. Karpe Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient Heart 97 2011 350 356 British Cardiac Society
97. A.C. Keech, P. Mitchell, P.A. Summanen, J. O'Day, T.M. Davis, M.S. Moffitt, M.R. Taskinen, R.J. Simes, D. Tse, E. Williamson, A. Merrifield, L.T. Laatikainen, M.C. d'Emden, D.C. Crimet, R.L. O'Connell, and P.G. Colman Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial Lancet 370 2007 1687 1697
98. A.C. Skulas-Ray, P.M. Kris-Etherton, W.S. Harris, J.P. Vanden Heuvel, P.R. Wagner, and S.G. West Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia Am. J. Clin. Nutr. 93 2011 243 252
99. E.M. Balk, A.H. Lichtenstein, M. Chung, B. Kupelnick, P. Chew, and J. Lau Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review Atherosclerosis 189 2006 19 30
100. M. Yokoyama, H. Origasa, M. Matsuzaki, Y. Matsuzawa, Y. Saito, Y. Ishikawa, S. Oikawa, J. Sasaki, H. Hishida, H. Itakura, T. Kita, A. Kitabatake, N. Nakaya, T. Sakata, K. Shimada, and K. Shirato Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis Lancet 369 2007 1090 1098
101. L. Hooper, R.L. Thompson, R.A. Harrison, C.D. Summerbell, A.R. Ness, H.J. Moore, H.V. Worthington, P.N. Durrington, J.P. Higgins, N.E. Capps, R.A. Riemersma, S.B. Ebrahim, and G. Davey Smith Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review BMJ 332 2006 752 760 Clinical research ed
102. S.H. Lee, S. Park, S.M. Kang, Y. Jang, N. Chung, and D. Choi Effect of atorvastatin monotherapy and low-dose atorvastatin/ezetimibe combination on fasting and postprandial triglycerides in combined hyperlipedemia J. Cardiovasc. Pharmacol. Ther. 2011 [Electronic publication ahead of print Mar 8].
103. J.K. Olijhoek, G.R. Hajer, Y. van der Graaf, G.M. Dallinga-Thie, and F.L. Visseren The effects of low-dose simvastatin and ezetimibe compared to high-dose simvastatin alone on post-fat load endothelial function in patients with metabolic syndrome: a randomized double-blind crossover trial J. Cardiovasc. Pharmacol. 52 2008 145 150
104. G.R. Hajer, G.M. Dallinga-Thie, L.C. van, Vark-van der Zee, and F.L. Visseren The effect of statin alone or in combination with ezetimibe on postprandial lipoprotein composition in obese metabolic syndrome patients Atherosclerosis 202 2009 216 224
105. C. Fievet, and B. Staels Combination therapy of statins and fibrates in the management of cardiovascular risk Curr. Opin. Lipidol. 20 2009 505 511
106. T. Prueksaritanont, C. Tang, Y. Qiu, L. Mu, R. Subramanian, and J.H. Lin Effects of fibrates on metabolism of statins in human hepatocytes Drug metab. dispos: biol. fate chem. 30 2002 1280 1287
107. T. Zhu, W.M. Awni, B. Hosmane, M.T. Kelly, D.J. Sleep, J.C. Stolzenbach, K. Wan, T.O. Chira, and R.S. Pradhan ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans J. Clin. Pharmacol. 49 2009 63 71
108. NCEP-expert-panel, third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report, Circulation 106 (2002) 3143-3421.
109. J.D. Brunzell, M. Davidson, C.D. Furberg, R.B. Goldberg, B.V. Howard, J.H. Stein, and J.L. Witztum Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation Diabetes Care 31 2008 811 822
110. K.E. Harchaoui, M.E. Visser, J.J. Kastelein, E.S. Stroes, and G.M. Dallinga-Thie Triglycerides and cardiovascular risk Curr. cardiol. rev. 5 2009 216 222
111. S.M. Grundy, J.I. Cleeman, C.N. Merz, H.B. Brewer Jr., L.T. Clark, D.B. Hunninghake, R.C. Pasternak, S.C. Smith Jr., and N.J. Stone Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
112. M. Miller, N.J. Stone, C. Ballantyne, V. Bittner, M.H. Criqui, H.N. Ginsberg, A.C. Goldberg, W.J. Howard, M.S. Jacobson, P.M. Kris-Etherton, T.A. Lennie, M. Levi, T. Mazzone, and S. Pennathur Triglycerides and cardiovascular disease: a scientific statement from the american heart association Circulation 123 2011 2292 2333
113. A.F. Stalenhoef, and J. de Graaf Association of fasting and nonfasting serum triglycerides with cardiovascular disease and the role of remnant-like lipoproteins and small dense LDL Curr. Opin. Lipidol. 19 2008 355 361
114. J. de Graaf, P. Couture, and A. Sniderman A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias Nat. clin. pract. 4 2008 608 618
115. C.T. Johansen, and R.A. Hegele Genetic bases of hypertriglyceridemic phenotypes Curr. Opin. Lipidol. 22 2011 247 253
116. G.M. Ray Antiretroviral and statin drug-drug interactions Cardiol. Rev. 17 2009 44 47
117. M. Kishimoto, T. Sugiyama, K. Osame, D. Takarabe, M. Okamoto, and M. Noda Efficacy of ezetimibe as monotherapy or combination therapy in hypercholesterolemic patients with and without diabetes J. Med. Invest. 58 2011 86 94